Foshan MMC Biotechnology Co., Ltd., a pioneer in the biotechnology industry, is proud to announce that it has been granted a U.S. patent for its groundbreaking method titled "METHOD FOR FLUORESCENT IMMUNOASSAY (FIA) AND CHEMILUMINESCENT  IMMUNOASSAY (CLIA) BASED ON ELECTROKINETIC ACCELERATION." This patent, awarded on January 16, 2024, underscores the company's commitment to innovation and excellence in the field of rapid molecular detection.

The patented method introduces a revolutionary approach to fluorescent immunoassay (FIA) and chemiluminescent immunoassay (CLIA), pivotal for rapid point-of-care testing (POCT). Specifically designed to expedite the detection process, this method employs electrokinetic acceleration to enhance the efficiency of immunoassays significantly.

The core of the patented technology involves a two-step process aimed at increasing the reaction rate of FIA and CLIA. The first step, sample acceleration, requires applying an actuating signal to a specially designed chip. This chip is pre-treated with a target molecule and includes an electrode sheet with coating molecules immobilized on it. Following this, the secondary antibody acceleration involves the dropwise addition of a secondary antibody to the chip, which, upon applying another actuating signal, binds to the secondary antibody. This innovative method promises to revolutionize the detection process by making it faster and more reliable, catering to the urgent demand for rapid diagnostics.

"Foshan MMC Biotechnology Co., Ltd. is at the forefront of technological innovation in biotechnology," said Dr. Xiaozhu Liu, CTO at Foshan MMC Biotechnology Co., Ltd. "This patent not only represents a significant milestone in our relentless pursuit of excellence but also reinforces our dedication to improving healthcare outcomes through advanced diagnostic solutions. We are excited about the potential impact this method will have on rapid testing and diagnostics worldwide.

This achievement is a testament to Foshan MMC Biotechnology Co., Ltd.'s ongoing commitment to advancing healthcare through innovative solutions. The company continues to invest in research and development, aiming to provide cutting-edge technologies that address the challenges of modern healthcare, particularly in the area of diagnostics.

专利详情如下：